Sun Pharma Advanced Research Company (SPARC) skids 2.21% to Rs 170 after the company said that the US drug regulator has ruled against its appeal related to Taclantis, its under-development product for the treatment of breast cancer.
The Office of New Drugs (OND) of the U.S. Food and Drug Administration (USFDA) has denied the company's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for Taclantis.Taclantis is a novel formulation of paclitaxel developed with SPARC's proprietary Nanotecton technology. Paclitaxel is one of the most widely used cytotoxic agent and is approved for the treatment of breast cancer, ovarian cancer, non small cell lung cancer and pancreatic cancer.
In its Appeal Denied letter, the OND requested the conductofa new Phase 3 study in metastatic breast cancer patients to support any potential re-submission of the Taclantis NDA. The company will review FDA's response and decide on appropriate next steps soon.
On a standalone basis, SPARC reported a net loss of Rs 67.62 crore in Q3 December 2020 as compared to a net loss of Rs 55.51 crore in Q3 December 2019. Net sales jumped 11.3% to Rs 21.81 crore in Q3 December 2020 over Q3 December 2019.
SPARC is engaged in research and experimental development on natural sciences and engineering. The company operates through pharmaceuticals research and development segment.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU